Asubsidiary of Endo is allying with US-based ophthalmics and injectables specialist Nevakar to develop and market five “differentiated” sterile injectable products in the US and Canada. Nevakar will take charge of developing and filing the products, using in the US the 505(b)(2) hybrid new drug application (NDA) pathway.
Asubsidiary of Endo is allying with US-based ophthalmics and injectables specialist Nevakar to develop and market five “differentiated” sterile injectable products in the US and Canada. Nevakar will take charge of developing and filing the products, using in the US the 505(b)(2) hybrid new drug application (NDA) pathway.
The deal signed with Endo Ventures Limited will see Endo’s Par Pharmaceutical Sterile Products division launch and distribute the products...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
